SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cash Cat

Cash Cat is trending as market participants debate its potential as a prominent memecoin on the Robinhood network, with some investors drawing comparisons to previous breakout tokens. While the community is actively divided between those aggressively accumulating the asset and skeptics labeling it a speculative gamble, the focus remains on its utility as a launchpad within the ecosystem.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly anticipate the release of Phase 3 IZAR-1 trial data, with community discussion focused on whether the results will establish the drug as a best-in-class treatment for psoriatic arthritis. Shareholders are actively debating the timing of this data release alongside upcoming quarterly earnings, while speculating on the potential for an acquisition given the company's strong clinical pipeline and strategic value to major pharmaceutical players.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing strong momentum as investors focus on its pivotal role in the CPO supply chain for next-generation AI infrastructure. The community is actively discussing the company's potential to scale alongside major industry players, with sentiment bolstered by recent earnings performance and expectations for long-term growth in the automotive and AI smart glasses sectors.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is experiencing heightened investor focus as the photonics sector faces a critical supply-demand imbalance, with major hyperscalers increasingly relying on advanced optical components to overcome AI data center bottlenecks. The stock is a focal point of ongoing community debate regarding the scalability of optical infrastructure, with market participants closely watching recent capacity expansions and strategic investments from industry leaders as key indicators for long-term growth.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh escalating geopolitical instability in the Strait of Hormuz against the company's potential windfall from disrupted global LNG supplies. The community is focused on the widening spread between U.S. natural gas costs and elevated international spot prices, debating whether this geopolitical volatility or the company's long-term operational growth will ultimately drive the stock's post-earnings performance.

Tower Semiconductor Ltd. engages in providing semiconductor solutions. It also offers technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical, and aerospace and defense. It focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Its designs enable a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. The company was founded in 1993 and is headquartered in Migdal Haemek, Israel.

Tower Semiconductor Ltd.

Tower Semiconductor is gaining momentum as market participants increasingly view it as a critical pick-and-shovel play within the AI infrastructure and silicon photonics supply chain. The community is actively tracking its technical support at key moving averages and analyzing strategic partnerships that position the company to benefit from the ongoing buildout of high-speed data center connectivity.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is currently trending as part of a broader sector rotation, with investors debating whether recent volatility represents a fundamental breakdown or a buying opportunity following the stock's significant pullback. Community discussion is heavily focused on the company's long-term backlog growth and its strategic positioning in the AI-geospatial intelligence market, while many participants are actively weighing its performance against the broader space complex.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings Inc. is drawing significant attention as investors monitor its upcoming earnings release amidst a sector-wide focus on the AI infrastructure supply chain. The community is heavily debating whether the stock's recent price volatility and valuation reset represent a prime buying opportunity for a long-term photonics leader or a signal of cooling demand for data center optics.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending as investors react to the company's shift from a development-stage entity to a commercial oncology player, with the community closely tracking the IBTROZI launch momentum and first-line patient adoption. Market sentiment is further bolstered by discussions around the potential for strategic M&A within the oncology sector and the long-term pipeline value of safusidenib.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as institutional interest builds following a strong earnings performance, with many in the community highlighting its successful growth in the ACA marketplace and effective use of AI-driven technology. While bullish investors view the stock's recent momentum as a sign of sustained re-rating, others remain cautious, debating the long-term impact of medical loss ratios and potential regulatory headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpyGlass Pharma,  Inc. Loss At -$19.864 Mln In Q2

(RTTNews) - SpyGlass Pharma, Inc. (SGP) reported Loss for second quarter of -$19.864 million...

Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Average Rating of "Moderate Buy" from Analysts

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. One...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened

Spyglass Pharma (NASDAQ:SGP) Shares Up 8.6% - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Hits New 1-Year Low - What's Next?

Spyglass Pharma (NASDAQ:SGP) Hits New 12-Month Low - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Trading Down 5.2%  - Here's Why

Spyglass Pharma (NASDAQ:SGP) Stock Price Down 5.2% - Time to Sell...

HC Wainwright Lifts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Spyglass Pharma in a report issued on Monday, March 30th...

Spyglass Pharma, Inc. (NASDAQ:SGP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a...

Spyglass Pharma (NASDAQ:SGP) Cut to "Sell" at Wall Street Zen

Wall Street Zen cut Spyglass Pharma from a "hold" rating to a "sell" rating in a research note on Saturday...

Spyglass Pharma (NASDAQ:SGP) Releases Earnings Results, Beats Expectations By $0.89 EPS

Spyglass Pharma (NASDAQ:SGP - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($5.72) earnings per share (EPS) for the quarter, topping analysts' consensus...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Time to Buy?

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Should You Buy...

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

SpyGlass Pharma Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGPSpyGlass Pharma Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest SGP News